ALAMEDA HOSPITAL
1. Target Overview & Investment Thesis
ALAMEDA HOSPITAL is a 66-bed under-performing / distressed in nan, CA with $106.4M in net patient revenue and a -62.7% operating margin. The hospital serves a payer mix of 38.5% Medicare, 8.5% Medicaid, and 53.1% commercial.
Thesis: Turnaround. Our ML models identify $7.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -62.7% to -55.3% (+736bps).
| Net Revenue HCRIS | $106.4M |
| Current EBITDA COMPUTED | $-66.7M |
| Operating Margin COMPUTED | -62.7% |
| Occupancy HCRIS | 58.0% |
| Revenue / Bed COMPUTED | $1.6M |
| Net-to-Gross HCRIS | 15.8% |
| Distress Probability ML | 45.5% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -62.7% places it below the state median. Among 132 size-comparable peers (33-132 beds), the median margin is -5.7%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (33-132), prioritizing same-state peers. 132 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| ALAMEDA HOSPITAL (Target) | CA | 66 | $106.4M | -62.7% |
| CONTRA COSTA REGIONAL MEDICAL | CA | 124 | $595.0M | -29.2% |
| RANCHO LOS AMIGOS NATL.REHAB.C | CA | 83 | $512.6M | 41.9% |
| USC NORRIS CANCER HOSPITAL | CA | 60 | $468.7M | 19.1% |
| EDEN MEDICAL CENTER | CA | 126 | $389.8M | 2.7% |
| SUTTER SANTA ROSA REGIONAL HOS | CA | 124 | $374.4M | -0.2% |
| ST. JOSEPH HOSPITAL - EUREKA | CA | 132 | $331.9M | -16.9% |
| KFH - FREMONT | CA | 100 | $296.2M | -6.6% |
| QUEEN OF THE VALLEY MEDICAL CE | CA | 119 | $293.8M | -16.7% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $7.8M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $2.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $2.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $2.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.3M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $68K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-66.7M |
| + RCM Uplift | +$7.8M |
| Pro Forma EBITDA | $-58.9M |
| Current Margin | -62.7% |
| Pro Forma Margin | -55.3% |
| WC Released (1x) | $4.1M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-102.7M | $-361.9M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-102.7M | $-431.4M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-92.4M | $-438.9M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-92.4M | $-506.1M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-112.9M | $-367.7M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-112.9M | $-441.1M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 132 hospitals with 33-132 beds
- Same-state prioritization (n=133)
- Comp margins: P25=-22.0% / P50=-5.7% / P75=2.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.